Literature DB >> 26625791

Burden Assessment of Thyroid cancer in Iran from 1990 to 2010: Lessons Obtained from Global Burden of Disease Report 2010.

Mitra Modirian1, Zahra Cheraghi, Shadi Rahimzadeh, Sahar Saeedi Moghaddam, Alireza Mosavi Jarrahi.   

Abstract

BACKGROUND: Thyroid tumors are generally regarded as rare malignancies. Nowadays, however, their global incidence is growing continuously partially due to western life style and utilization of more sensitive methods of early detection. It is approximately three times more prevalent in females than in males. Most cases of thyroid cancer are asymptomatic nodules or just have local cervical symptoms or adenopathy in early stages.
MATERIALS AND METHODS: The Global Burden of Diseases report 2010 study (released 3/2013) profited from 100 collaborators worldwide and used a vast network of data on health outcomes, vital registries, and population surveys. It shared many of the Global Burden of Diseases 1990 principal databases such as all available data on injuries, diseases, risk factors, as well as comparable metrics, and used different scientific approved methods to estimate important health status data like: death rate, life expectancy, healthy adjusted life expectancy, disability-adjusted life years (DALY), years of living lost due to premature death and years of life with disabilities.
RESULTS: DALY as thyroid cancer burden per 100,000 Iranian populations had increased by about 14% during 1990 to 2010 in all ages; from 6.1 (95% UI 4.2-9.74) years in 1990 to 6.95 (95% UI 5.06-9.18) years in 2010 in both sex. The 2010 peak age-group was estimated at 45-49 years in males and 40-45 years in females.

Entities:  

Mesh:

Year:  2015        PMID: 26625791     DOI: 10.7314/apjcp.2015.16.17.7743

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  3 in total

1.  Global, regional, and national burden and quality of care index (QCI) of thyroid cancer: A systematic analysis of the Global Burden of Disease Study 1990-2017.

Authors:  Sina Azadnajafabad; Sahar Saeedi Moghaddam; Esmaeil Mohammadi; Negar Rezaei; Erfan Ghasemi; Nima Fattahi; Arya Aminorroaya; Reza Azadnajafabad; Armin Aryannejad; Nazila Rezaei; Shohreh Naderimagham; Vahid Haghpanah; Ali H Mokdad; Hossein Gharib; Farshad Farzadfar; Bagher Larijani
Journal:  Cancer Med       Date:  2021-03-05       Impact factor: 4.452

2.  National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019.

Authors:  Mohammadreza Azangou-Khyavy; Sahar Saeedi Moghaddam; Negar Rezaei; Zahra Esfahani; Nazila Rezaei; Sina Azadnajafabad; Mohammad-Mahdi Rashidi; Esmaeil Mohammadi; Seyed Mohammad Tavangar; Hamidreza Jamshidi; Ali H Mokdad; Mohsen Naghavi; Farshad Farzadfar; Bagher Larijani
Journal:  Sci Rep       Date:  2022-08-02       Impact factor: 4.996

3.  The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the Global Burden of Disease Study.

Authors:  Mimi Zhai; Dan Zhang; Jianhai Long; Yi Gong; Fei Ye; Sushun Liu; Yamin Li
Journal:  Cancer Med       Date:  2021-05-18       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.